The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Weight loss drugs like Zepbound and Novo Nordisk's Ozempic aren't covered under Medicare, but can be covered when prescribed to treat another disease like sleep apnea. The Biden administration ...

While sales of both drugs have been rising on a sequential and yearly basis, the reported figures missed the consensus estimate of $4.3 billion for Mounjaro and $2.2 billion for Zepbound.

But Lilly's Mounjaro and Zepbound have proved more efficacious than either Ozempic and Wegovy. While Novo Nordisk still owns about 56% of the GLP-1 market, Lilly's sales have been growing faster ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in sales could portend weaker long-term potential for this market. Lilly is positioned to remain the ...

(Reuters) -Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed ...

Eli Lilly expects about $3.5 billion in revenue for its diabetes treatment Mounjaro and $1.9 billion for its obesity drug Zepbound. CEO Dave Ricks told CNBC that the company has "tons of supply ...

Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA ... and as an injectable (Ozempic® and Wegovy ...

BioSpace reported that Eli Lilly faces fierce competition from Novo Nordisk (NYSE:NVO)'s Wegovy and Ozempic, which has led to lower-than-expected demand for Eli Lilly's weight loss and diabetes ...

Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA ... in an oral form (Rybelsus®) and as an injectable (Ozempic® ...